Could cilostazol beat aspirin at preventing strokes?
NCT ID NCT07180472
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study compares cilostazol, aspirin, and clopidogrel in 632 people who recently had a stroke due to cerebral small vessel disease. The goal is to see if cilostazol is better at preventing another stroke and slowing disease progression, with fewer bleeding risks. Participants will take one of the three drugs and be followed for outcomes like new strokes, cognitive decline, and disability.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cilostazol
What this could lead to
If it works, this could provide a safer and more effective option to prevent recurrent strokes and slow cognitive decline in people with cerebral small vessel disease.
What could go wrong
This is a Phase 4 trial, but results may not apply to all patients. Cilostazol may not prove superior to existing drugs, and bleeding risks remain possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CEREBRAL SMALL VESSEL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••